Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713223 | 1.00 | LMNA (0.68) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL16326401 | 0.94 | LMNA (0.75) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8232803 | 0.87 | LMNA (0.81) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL713327 | 0.85 | LMNA (0.49) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4612058 | 0.85 | LMNA (0.49) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8226795 | 0.84 | LMNA (0.68) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8234958 | 0.83 | LMNA (0.74) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7642884 | 0.79 | LMNA (0.69) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL17189637 | 0.79 | LMNA (0.67) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9892436 | 0.79 | LMNA (0.60) | LMNAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-1984384-B1 | Conotoxin analogues, and methods for synthesis of intramolecular dicarba bridge containing peptides | SYNGENE LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-8759480-B2 | Contoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2014-06-24 | — | — | US | disclosed |
| EP-1984386-B1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LTD (AU) | 2013-10-09 | — | — | EP | disclosed |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-05-16 | — | — | US | disclosed |
| US-8362204-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2013-01-29 | — | — | US | disclosed |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2012-06-07 | — | — | US | disclosed |
| US-8188217-B2 | — | — | 2012-05-29 | — | — | US | disclosed |
| US-8124726-B2 | Contoxin analogues and methods for synthesizing same | MONASH UNIVERSITY (AU) | 2012-02-28 | — | — | US | disclosed |
| US-7745573-B2 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2010-06-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | MONASH UNIVERSITY (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | SYNGENE LIMITED (AU) | 2009-06-04 | — | — | US | disclosed |
| US-7538190-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2009-05-26 | — | — | US | disclosed |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | OTC, NBAS, IDH2 | LMNA 880/4885MEN1 1229/4885KMT2A 530/4885 |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, CDCA2 | LMNA 519/4885MEN1 73/4885KMT2A 377/4885 |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | OTC, NBAS, IDH2 | LMNA 880/4885MEN1 1229/4885KMT2A 530/4885 |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | VIP, CANX, INHA | LMNA 363/4885MEN1 1446/4885KMT2A 2975/4885 |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | VIP, CANX, PDIA5 | LMNA 416/4885MEN1 1512/4885KMT2A 2489/4885 |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | LMNA 538/4885MEN1 67/4885KMT2A 426/4885 |
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, MTCL3 | LMNA 538/4885MEN1 67/4885KMT2A 426/4885 |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | OTC, NBAS, IDH2 | LMNA 880/4885MEN1 1229/4885KMT2A 530/4885 |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | VIP, NRDC, INHA | LMNA 529/4885MEN1 956/4885KMT2A 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.